Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06663787 · ClinicalTrials.gov registry record
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)
A clinical trial of Breast Cancer Metastatic and HER2 + Breast Cancer, sponsored by Nagoya City University.
- Active
- Registry status
- 50
- Enrollment target
- 4
- Study locations
NCT06663787: Active study of Breast Cancer Metastatic and HER2 + Breast Cancer, sponsored by Nagoya City University.
NCT06663787 is a study of Breast Cancer Metastatic and HER2 + Breast Cancer that is active but no longer recruiting, run by Nagoya City University. The registered enrollment target is 50 participants, below the 89-participant average among 17 other Breast Cancer Metastatic trials with a reported enrollment target (44% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06663787, a study of Breast Cancer Metastatic and HER2 + Breast Cancer, is active but no longer recruiting, sponsored by Nagoya City University.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
Anti-HER2 therapy, such as trastuzumab and pertuzumab, has significantly improved long-term survival in HER2-positive breast cancer. The updated data of the CLEOPATRA trial showed significant Kaplan-Meier curves, suggesting the potential for a cure. However, the efficacy of maintenance therapy in long-term responders remains unexplored. This study will assess MRD in unresectable HER2-positive breast cancer cases with long-term response using the Signatera™ ctDNA assay, which could contribute to future treatment strategy development.
Primary Outcome
To assess the status of ctDNA in CR patients with/without continuing treatment, or PR patients with continuing treatment
Conditions Studied
Interventions
- DRUG Trastuzumab (Herceptin)
- DIAGNOSTIC_TEST SIgnatera
Study Locations (4)
Aichi-ken
- Aichi Cancer Center - Nagoya
- Nagoya City University - Nagoya
Texas
- Natera - San Carlos
Tokyo
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research - Tokyo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT06663787 still lists
NCT06663787 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 89-participant average among 17 other Breast Cancer Metastatic trials with a reported enrollment target (44% lower).
The record links to 2 conditions, with Breast Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which Trastuzumab (Herceptin) is the first listed.
NCT06663787 reports a single indexed study location in Aichi-ken, Texas, Tokyo.
Frequently Asked Questions
What is clinical trial NCT06663787 about?
NCT06663787 is a clinical study titled "Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)". Anti-HER2 therapy, such as trastuzumab and pertuzumab, has significantly improved long-term survival in HER2-positive breast cancer. The updated data of the CLEOPATRA trial showed significant Kaplan-Meier curves, suggesting the potential for a cure. However, the efficacy of maintenance therapy in lo...
What is the current status of trial NCT06663787?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2024-04-01. Estimated completion is 2025-12-31.
What conditions does trial NCT06663787 study?
This clinical trial studies the following conditions: Breast Cancer Metastatic, HER2 + Breast Cancer.
What interventions are being tested in trial NCT06663787?
The interventions under investigation include: Trastuzumab (Herceptin) (DRUG), SIgnatera (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06663787?
This trial is sponsored by Nagoya City University, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06663787 being conducted?
This trial has 4 study locations across Texas, Aichi-ken, Tokyo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06663787's enrollment target sits among peer trials
50 9th of 17 higher than 9 of 17 other Breast Cancer Metastatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
RECRUITING · Phase 2
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
RECRUITING · NA
-
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
RECRUITING · Phase 1
-
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI